Neuland Laboratories reported a consolidated net profit of ₹1,476.73 lakh for the quarter ended June 30, 2026, representing a 960% year-on-year increase from ₹139.00 lakh in Q1FY25. This significant turnaround in profitability was driven by a 119% surge in revenue from operations, which reached ₹6,415.77 lakh compared to ₹2,927.53 lakh in the corresponding period of the previous fiscal year. The strong top-line growth, combined with effective cost management, resulted in a profit before tax of ₹1,978.47 lakh, up from ₹175.70 lakh a year ago.

The Board of Directors approved the unaudited financial results at a meeting held on August 5, 2026, in compliance with Regulation 30 and Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by the Statutory Auditors, MSK A & Associates LLP. The consolidated figures include results from wholly owned subsidiaries Neuland Laboratories Inc., USA, and Neuland Laboratories K.K., Japan. Management noted that the interim financial information of these subsidiaries, reflecting total revenue of ₹606.54 lakh and net profit after tax of ₹31.12 lakh, was not material to the Group.

In a strategic move to expand its sterile API capabilities, Neuland Laboratories announced a long-term Contract Development and Manufacturing Organization (CDMO) partnership with Gland Pharma Limited. Under this collaboration, Gland Pharma will establish a dedicated sterile manufacturing suite at its JNPC facility in Visakhapatnam to support Neuland’s growing demand for sterile APIs used in microparticle depot products. The new facility, designed to add approximately 1,400 kg of annual capacity, will be constructed and operated to cGMP, USFDA, and EU standards. To secure the obligations under the associated Loan Licence Agreement, Neuland executed an irrevocable corporate guarantee of ₹40 crores in favour of Gland Pharma Limited. The promoter group has no interest in this transaction, which was executed at arm's length.

Financial Performance Breakdown

Revenue growth was broad-based across geographies. Europe contributed ₹3,034.58 lakh, up significantly from ₹944.12 lakh in Q1FY25. Revenue from the USA and North America rose to ₹1,996.74 lakh from ₹657.84 lakh, while India operations generated ₹832.64 lakh. The Rest of the World segment contributed ₹551.82 lakh. Earnings per share stood at ₹115.10, a substantial increase from ₹10.83 in the previous year's quarter.

Capacity Expansion Plans

To cater to growing customer demand, the Board approved an enhancement of manufacturing capacity at Unit 1 located in Sangareddy District, Telangana. The existing capacity of 376.5 KL, currently utilized at 91%, will be increased by 18 KL. The expansion is expected to be completed within 6–7 months and requires an investment of ₹39.8 crores (including GST), which will be financed through internal accruals. This capital expenditure aims to maintain supply resilience and meet increasing order inflows without impacting the company’s current liquidity position.

Neuland Laboratories Limited shareholders approved a final dividend of ₹34 per equity share for the financial year ended March 31, 2026, during its 42nd Annual General Meeting (AGM) held on August 4, 2026. The resolution received unanimous support from voting shareholders, with 82,55,773 votes cast in favor out of 82,55,773 valid votes polled. This payout represents a dividend yield of 340% on the face value of ₹10 per share.

The meeting, conducted via Video Conferencing (VC) and Other Audio-Visual Means (OAVM) in compliance with Ministry of Corporate Affairs (MCA) and Securities and Exchange Board of India (SEBI) circulars, also addressed key governance matters. Shareholders reappointed Dr. Davuluri Rama Mohan Rao as a Director upon his retirement by rotation and appointed Dr. Mauricio Futran as a Non-Executive Non-Independent Director. The Board’s recommendation to pay commissions to Non-Executive Directors and ratify the remuneration of Cost Auditors was also approved.

Voting Results Overview

A total of 81 members attended the meeting through VC/OAVM. The voting participation rate was approximately 64.34% of the total outstanding shares. Promoter and Promoter Group holdings accounted for 99.34% of the votes polled, while Public-Institutions contributed 84.51% of their eligible votes. Public-Non Institutions had a lower participation rate of roughly 3.08%.

Governance and Procedural Details

The AGM was chaired by Dr. D.R. Rao, Executive Chairman. Ms. Sarada Bhamidipati, Company Secretary & Compliance Officer, managed the proceedings. The Statutory and Secretarial Auditor’s Reports for FY26 contained no qualifications, observations, or adverse remarks.

Shaik Razia, Partner at D. Hanumanta Raju & Co., served as the Scrutinizer for the e-voting process conducted via the National Securities Depository Limited (NSDL) platform. Remote e-voting was open from August 1, 2026, to August 3, 2026. During the meeting, shareholders who had not voted remotely were given the opportunity to cast their votes electronically, with the facility remaining open for 15 minutes after the conclusion of the meeting.

Minor dissent was observed in the resolutions concerning the appointment of Dr. Futran and the reappointment of Dr. Rao, primarily from public institutional investors. However, all resolutions were passed with the requisite majority under Regulation 44 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.